Patients with multiple myeloma administered daratumumab in combination with bortezomib and dexamethasone demonstrated improvements in overall survival compared with those given bortezomib and dexamethasone alone.
At a live virtual event, Sumit Madan, MD, broke down the use of quadruplet therapies in the frontline setting for patients with multiple myeloma and how to care for patients when they relapse on treatment.
During a Targeted Oncology case-based roundtable event, Yvonne A. Efebara, MD, MPH, discussed the role of triplet and quadruplet systemic therapies for newly diagnosed multiple myeloma and the use of autologous stem cell transplant.
After an update from the phase 3 DREAMM-3 study the use of belantamab monotherapy for previously treated patients with relapsed or refractory multiple myeloma was pulled from US market authorization by request of the FDA.
Retrospective real-world evidence shows that patients who relapse after B-cell maturation antigen chimeric antigen receptor T-cell therapy may have multiple treatment options, including salvage therapy and T-cell engagers.